317. Trifunctional protein deficiency Clinical trials / Disease details
Clinical trials : 4 / Drugs : 9 - (DrugBank : 4) / Drug target gene : 1 - Drug target pathway : 1
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05411835 (ClinicalTrials.gov) | August 1, 2022 | 27/5/2022 | Oral Ketones and Exercise Among Patients With Long-chain Fatty Acid Oxidation Disorders | Safety and Tolerability of Oral Ketones and Exercise Among Patients With Long-chain Fatty Acid Oxidation Disorders | Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency;Carnitine Palmitoyltransferase Deficiency 2;Very Long Chain Acyl Coa Dehydrogenase Deficiency;Trifunctional Protein Deficiency | Dietary Supplement: Nutritional Ketone Supplement;Dietary Supplement: Isocaloric Placebo Supplement | Oregon Health and Science University | NULL | Recruiting | 18 Years | N/A | All | 5 | Early Phase 1 | United States |